Aarti Drugs, Cipla, Crompton Greaves, IIFL Securities, Nippon Life India Asset Management, Tata Chemicals and L&T Technology Services are among 12 companies that are scheduled to announce their March quarter earnings today.
Healthcare majors, including Cipla, Lupin, Wockhardt, Glaxosmithkline and Mankind Pharma, on Thursday granted interim relief by Delhi High Court which stayed till March 21 the ban imposed by the Centre on sale of some of thei
The acquisition will provide a launch pad to introduce Cipla’s pipeline of products in respiratory and injectables, among others, in the coming years Cipla’s UK arm, Cipla (EU) has closed the transaction to acquire tw
Domestic sales reduced to Rs 1,194 crore Cipla announced its unaudited consolidated financial results for the quarter ended December 31, 2015 (Q3). Income from operations grew by 12.3 per cent to Rs 3,107 crore, up from Rs. 2
Acquires additional five per cent stake from his wife Farida Hamied In a move aimed at realignment of family shareholding, Cipla patriarch YK Hamied has increased his stake in the homegrown drug major to over 20 per cent by a
In November last year, the company signed an agreement to sell 26.11 per cent in Cipla Health to FIL Capital Investments (Mauritius) II Cipla has received approval from fair trade regulator CCI to sell about 26 per cent stake
Appoints Umang Vohra as its Global Chief Operating Officer Cipla announced the creation of a six member Management Council that will be the apex executive leadership team for the company. This is part of its ongoing transform
Cutisera has been developed by Stempeutics Cipla has launched a novel “5 in 1” anti-ageing skin care product Cutisera developed by Stempeutics. Cutisera has been developed using bio-active factors derived from human adult
Petitions were filed by pharma companies and an association of medicine manufacturing firms challenging the government’s new drug pricing order that asked them to slash prices of 348 medicines The Delhi High Court has t
She received the Padma Shri Award in 2007 from Government of India Cipla has announced the appointment of Naina Lal Kidwai as an independent director on its board effective November 6, 2015. Until recently Kidwai was Executiv
Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant Ltd for a consideration of USD 25,775,000 to focus on biological segment under its arm Cipla BioTec.
Divests its remaining stake in Hong Kong-based Biomab Holding to focus on global development under Cipla BioTec Cipla has entered into a definitive agreement to sell its entire 25 per cent stake in Biomab Holding Limited, Hon
As many as nine issues have been raised by the regulator under ‘Form 483’ regarding manufacturing practices in the plant Cipla’s Indore plant has come under the scanner of US health regulator for manufacturi